1 **Full title:** Is the BioNTech-Pfizer COVID-19 vaccination effective in elderly populations?

2 Results from population data from Bavaria, Germany

3 **Short title:** Effectiveness of BNT162b2 vaccination in the elderly

4 Delphina Gomes^{1¶}, Andreas Beyerlein^{1¶}, Katharina Katz², Gabriele Hoelscher², Uta

5 Nennstiel², Bernhard Liebl², Klaus Überla³, Rüdiger von Kries^{1*}

6 ¹ Institute of Social Pediatrics and Adolescent Medicine, Division of Pediatric Epidemiology,

7 Ludwig-Maximilians-University, Munich, Germany

8 ² Bavarian Health and Food Safety Authority, Oberschleissheim, Germany

9 ³ Institute of Clinical and Molecular Virology, Universitätsklinikum Erlangen, Friedrich-

10 Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

11 *ruediger.kries@med.uni-muenchen.de

12 [¶]These authors contributed equally to this work.

13 **Abbreviations:** CI, confidence interval; COVID-19, coronavirus disease; HR, hazard ratios;

14 KM, Kaplan-Meier; LGL, Bavarian Health and Food Safety Authority; PHM, Public Health

15 Microbiology; RKI, Robert Koch-Institute; RT-PCR, reverse transcription polymerase chain

16 reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; STIKO, Standing

17 Committee on Vaccination; VE, vaccine efficacy.

18 Abstract

19 Background

20 The effect of the BioNTech-Pfizer BNT162b2 vaccination in the elderly (≥ 80 years)
 21 could not be fully assessed in the BioNTech-Pfizer trial due to low numbers in this age group.
 22 We aimed to evaluate the effectiveness of the BioNTech-Pfizer (BNT162b2) vaccine to
 23 prevent SARS-CoV-2 infection and severe outcomes in octo- and novo-generians in a
 24 German state setting.

25 Methods and Findings

26 A prospective observational study of 708,187 persons aged ≥ 80 years living in
 27 Bavaria, Germany, was conducted between Jan 9 to Apr 11, 2021. We assessed the vaccine
 28 efficacy (VE) for two doses of the BNT162b2 vaccine with respect to SARS-CoV-2 infection
 29 and related hospitalisations and mortality. Additionally, differences in VE by age groups ≥ 80
 30 to ≤ 89 years and ≥ 90 years were studied. Analyses were adjusted by sex.

31 By the end of follow-up, 63.8% of the Bavarian population ≥ 80 years had received one
 32 dose, and 52.7% two doses, of the BNT162b2 vaccine. Two doses of the BNT162b2 vaccine
 33 lowered the proportion of SARS-CoV-2 infections and related outcomes, resulting in VE
 34 estimates of 68.3% (95% confidence interval (CI) 65.5%, 70.9%) for infection, 73.2% (95%
 35 CI 65.3%, 79.3%) for hospitalisation, and 80.1% (95% CI 80.0%, 89.0%) for mortality. Sex
 36 differences in the risk of COVID-19 outcomes observed among unvaccinated persons
 37 disappeared after two BNT162b2 vaccine doses. Overall, the BNT162b2 vaccine was equally
 38 efficacious in octo- and novo-generians.

39 Conclusions

40 Two doses of BioNTech-Pfizer's BNT162b2 vaccine is highly effective against COVID-19
 41 outcomes in elderly persons.

42 Introduction

43 Global research on coronavirus disease (COVID-19) has shown that an increasing age is the
 44 most relevant risk factor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
 45 infections.¹ The high risk for poor outcomes of SARS-CoV-2 infection in the elderly is likely
 46 to be due to chronic comorbidities such as hypertension and cardiovascular disease,²
 47 diminishing physiological functions including that of the respiratory system,³ and impaired
 48 immune response.⁴

49 The high SARS-CoV-2 infection case fatality rates in the elderly population⁵ has guided
 50 prioritization of this age group in several countries, including Germany.^{6,7} The COVID-19
 51 disease vaccination programme in Germany was launched on Dec 27, 2020 using the
 52 BioNTech-Pfizer mRNA BNT162b2⁸ vaccine which requires two doses within at least 21
 53 days for full protection.⁹ Other vaccines including Moderna (mRNA-1273), Oxford-
 54 AstraZeneca (ChAdOx1 nCoV-19), and Johnson & Johnson (Ad26.COV2.S) were licensed
 55 for use in Germany on Jan 6, 2021, Jan 29, 2021, and Mar 11, 2021, respectively.

56 In this study, we used vaccine uptake records of the large population of individuals aged ≥ 80
 57 years in Bavaria ($n \geq 700,000$), Germany, to evaluate the vaccine efficacy (VE) of the
 58 BNT162b2 vaccine with respect to SARS-CoV-2 infection or COVID-19-related
 59 hospitalisation or mortality in this age group. We further assessed whether VE differed
 60 between age groups ≥ 80 to ≤ 89 years and ≥ 90 years.

61 **Methods**

62 **Study design and population**

63 The federal state of Bavaria is located in the South-eastern part of Germany. Of its nearly 13
64 million inhabitants, 831,499 (6.3%) persons were aged 80 years and above (males 38.6%,
65 females 61.4%) by 31 Dec, 2019¹⁰ and were considered as reference population in the present
66 analysis.

67 **The German vaccination programme**

68 The German Ministry of Health outlined recommendations for COVID-19 vaccination in day-
69 to-day care practices and designated vaccination centres for implementation in respective
70 German states. All vaccines used until Apr 30, 2021 in Germany required two doses of the
71 same vaccine, according to the Standing Committee on Vaccination (STIKO).⁷

72 Data on the COVID-19 vaccination was collected by authorized staff of the vaccination
73 centers and vaccination teams and entered in the Bavarian Corona vaccination portal
74 “BayIMCO”. During the study period cumulative vaccination data was transferred to the
75 Robert Koch-Institut (RKI), because the transmission of records was not yet possible. The
76 Bavarian Health and Food Safety Authority (LGL) could receive anonymous records for
77 regional studies.

78 Aggregated level data on vaccination uptake in Bavaria per calendar week until Apr 11, 2021
79 were used for this study. Vaccination uptake data for persons aged ≥ 80 years included
80 information on vaccination type (BNT162b2, ChAdOx1 nCoV-19, and mRNA-1273), number
81 of vaccination doses received (1 or 2), sex, and age group (≥ 80 to < 85 years, ≥ 85 to < 90
82 years, ≥ 90 to < 95 years, and ≥ 95 years).

83 **Testing for SARS-CoV-2 infection**

84 Following the mandate given by the German Ministry of Health, notification of SARS-CoV-2
 85 infections became obligatory since Jan 30, 2020.¹¹ A positive COVID-19 case was defined as
 86 a person with a laboratory confirmation by detection of the SARS-CoV-2 virus by reverse
 87 transcription polymerase chain reaction (RT-PCR).^{12,13} Samples were tested for SARS-CoV-2
 88 infection at the Public Health Microbiology (PHM) laboratory of the LGL,¹⁴ private hospitals
 89 and university laboratories, and in routine care.¹³ Further details on the Bavarian strategy of
 90 SARS-CoV-2 testing can be found elsewhere.¹³ The data were collected at the public health
 91 offices and pseudo-anonymously forwarded to the LGL.

92 Data on all COVID-19 cases aged ≥ 80 years in Bavaria between Jan 9, 2021 to Apr 11, 2021
 93 was extracted from the LGL data bank. We used the data up until Apr 11, 2021 because as of
 94 Mar 31, 2021 vaccination was also implemented by general practitioners, who document
 95 vaccinations in a different platform and format. Thus, uniform vaccination uptake data were
 96 no longer available.

97 Case data included information on age, sex, whether an RT-PCR test was performed, date of
 98 infection, hospitalisation status, date and reasons of hospitalisation, mortality status, date and
 99 reasons of mortality, vaccination dose (1 or 2), as well as date and type of the last COVID-19
 100 vaccination.

101 **Outcomes**

102 We assessed VE for SARS-CoV-2 infection, COVID-19-related hospitalisation, and COVID-
 103 19-related mortality. A case with a SARS-CoV-2 infection was defined as a person with a
 104 positive RT-PCR test result. All SARS-CoV-2 infections included both symptomatic and
 105 asymptomatic cases. Hospitalisation was defined as admission to hospital with a positive RT-

PCR test result. A COVID-19-related mortality was defined as a person with a positive RT-PCR test result who died because of or in temporal relation to a SARS-CoV-2 infection.

Exclusion criteria for analysis

The analysis was limited to persons aged ≥ 80 years in Bavaria. We excluded observations with any of the following conditions: a) the infection was not confirmed by a positive RT-PCR test result, b) the infection was reported to have occurred before vaccination, c) the infection was related to a hospitalisation or mortality which occurred before 9th Jan, 2021, d) the vaccination was performed already in 2020, e) the person received another vaccine than BNT162b2). The exclusion criteria d) and e) applied also for the vaccine uptake dataset, with 29,071 persons already vaccinated in 2020, and 40,049 persons and 54,192 persons vaccinated with Moderna (mRNA-1273) or Oxford-AstraZeneca (ChAdOx1 nCoV-19), respectively, leaving a final number of $n=708,187$ for our analysis. There were no vaccinations with Johnson & Johnson (Ad26.COV2.S) recorded in the data because procurement was still outstanding during the course of the study.

Statistical analyses

To assess VE for each outcome, we combined the information from the vaccination uptake dataset with aggregate level data and from the SARS-CoV-2 infection dataset with individual patient data. The uptake data were used to calculate the number of vaccinated and unvaccinated persons per calendar week in 2021. Persons who were vaccinated with the BNT162b2 vaccine between Jan 9, 2021 (calendar week 1) and Apr 11, 2021 (calendar week 14) contributed to the follow-up of both unvaccinated and vaccinated persons. For example, if a person was vaccinated in calendar week 5, he/she was regarded as under follow-up for 4 weeks in the unvaccinated group and for the subsequent 10 weeks in the vaccinated group, respectively (and as censored thereafter in both cases).

With the combined vaccination uptake and infection data, we calculated Kaplan-Meier (KM) plots, p-values from log-rank tests, and hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) from Cox's proportional hazard models for time to SARS-CoV-2 infection by vaccination group. Time to any SARS-CoV-2 infection, time to SARS-CoV-2 infection with later hospitalisation, and time to SARS-CoV-2 infection leading to mortality were investigated as separate outcome variables. In case the date of COVID-19 related hospitalisation or mortality was earlier than the date of confirmed SARS-CoV-2 infection, the date of SARS-CoV-2 infection was set to the date of hospitalisation or mortality, respectively. All events were inversely weighted by the number of SARS-CoV-2 infections per calendar week in the age group ≥ 80 years to account for temporal changes in infection risk. Having two vaccination doses was used as the main exposure variable and compared to having no vaccination, respectively. All analyses were done for the whole age group ≥ 80 years and the HRs were additionally stratified by age ≥ 80 to ≤ 89 years and ≥ 90 years. Furthermore, the KM plots were stratified by sex, and the HRs were calculated with and without adjustment for sex. VE was derived as 1 minus HR.

All analyses were carried out using R 3.6.3. The analysis code is available at <https://osf.io/e9qm6/>.

Role of the funding source

The funder had no role in the study design, data analysis, interpretation, or writing of the report. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Results

Vaccine uptake in Bavaria in elderly persons

Until Apr 11, 2021, 63.8% elderly persons received one and 52.7% received the second BNT162b2 vaccination dose in Bavaria (Figure 1).

Fig 1. Uptake of BNT162b2 vaccine in persons ≥ 80 years in Bavaria.

Confirmed COVID-19 cases in Bavaria in elderly persons

Within the follow-up period, there were 11,228 Bavarian persons aged ≥ 80 years with a confirmed SARS-CoV-2 infection based on a positive RT-PCR test (Fig 2). After excluding vaccinated cases with missing information on vaccine dose or type and those who were not vaccinated with the BioNTech-Pfizer BNT162b2 vaccine (n=135), a total of 1,148 vaccinated cases were considered in the vaccination group. Of these included vaccinated cases, 44.9% were partially and 55.1% were fully vaccinated with the BNT162b2 vaccine.

163 **Fig 2. Flow chart of the study population.**

164 The mean age of the included cases was 86.1 years (SD 4.9 years) and 35.5% were males.
 165 There were 1,349 cases who were hospitalized and 1,731 cases who died due to SARS-CoV-2
 166 infection. The proportion of COVID-19-related hospitalisation did not differ according to
 167 vaccination status (from Chi-square test $p=0.135$). However, the proportion of COVID-19-
 168 related mortality was significantly lower in vaccinated persons compared to persons not
 169 vaccinated (from Chi-square test $p<0.0001$).

Risk of SARS-CoV-2 infection and related outcomes

In persons aged ≥ 80 years, having received two compared to no BNT162b2 vaccination doses was associated with a substantially lower cumulative risk of getting a SARS-CoV-2 infection (0.41% versus 1.25% after 70 days, Figure 3A). The estimate for VE after 2 doses of the BNT162b2 vaccine to prevent SARS-CoV-2 infection was 68.3% (95% CI 65.5%, 70.9%) (Figure 4A).

The risk of COVID-19-related hospitalisation (0.04% versus 0.19% after 70 days) and COVID-19-related mortality (0.03% versus 0.20% after 70 days) were also lower after two doses of the BNT162b2 vaccine (Figure 3B, Figure 3C). In the group of unvaccinated persons, the risk of infection was higher in females than in males and the risk for hospitalisation and mortality was higher in males than in females. After two doses of the BNT162b2 vaccine, females showed a significantly higher cumulative infection risk than males ($p < 0.0001$ from log-rank test), while there were no significant sex differences for VE with respect to hospitalisation ($p = 0.91$) and mortality ($p = 0.77$), respectively.

By the end of the follow-up period, VE for COVID-19-related hospitalisation and COVID-19-related mortality was 73.2% (95% CI 65.3%, 79.3%) and 85.1% (95% CI 80.0%, 89.0%), respectively (Figure 4B, Figure 4C). Estimates of VE in octo- and novo-generians overlapped.

S1 Figure presents VE based on the HR for SARS-CoV-2 infection and related outcomes in cases with one or more doses of the BNT162b2 vaccination. The trends in risk of SARS-CoV-2 infections and related outcomes were similar after either ≥ 1 dose or both doses of the BNT162b2 vaccine. However, VE for all outcomes were lower in persons with at least 1 than in persons with both doses of the BNT162b2 vaccine.

Fig 3. Risk of SARS-CoV-2 infection and related outcomes after two BNT162b2 vaccine doses in Bavarian persons aged 80 years and above.

194 **Fig 4. Vaccine efficacy to prevent SARS-CoV-2 infection and related outcomes after two**
 195 **BNT162b2 vaccine doses compared to none in Bavarian persons aged 80 years and**
 196 **above.**

197 Vaccine efficacy was calculated as $1 - \text{HR}$, adjusted for sex. CI, confidence interval; HR,
 198 hazards ratio; VE, vaccine efficacy.

Discussion

In this population-based analysis of all Bavarian persons aged ≥ 80 years with suitable follow-up between Jan 9, 2021 and Apr 11, 2021, we found a high protection against SARS-CoV-2 infection and mortality after the second dose of the BNT162b2 vaccine. This association did not differ by age above ≥ 80 to ≤ 89 years and ≥ 90 years. In the unvaccinated group, women were more likely to be infected than men whereas men were more likely to be hospitalized or die from COVID-19. Sex differences in the risk of hospitalisation and mortality in the absence of vaccination disappeared widely after vaccination.

Population-based studies to evaluate the efficacy of COVID-19 vaccines have shown that a single dose of the BNT162b2 vaccine had an efficacy between 42% and 75% against SARS-CoV-2 infection, between 43% and 85% against COVID-19-related hospitalisation, and between 51% and 72% against COVID-19-related mortality after at least 14 days.¹⁵ Overall, the estimates of VE increased after the second dose.¹⁵ There are scarce studies addressing VE after BNT162b2 vaccination in persons 80 years and above and none distinguishing VE in octo- and novo-genarians.

In the efficacy study on the BioNTech-Pfizer trial, VE to reduce SARS-CoV-2 infection was 94.7% in persons ≥ 65 years and 100.0% in persons ≥ 75 years. However, the CI for the VE estimates included null which could be possibly due to the low proportion of elderly persons in their study. Our real life data of elderly Bavarian persons, we found an overall VE of 68.3% after two doses with small 95% confidence bands. The efficacy of 68.3% against any infection after two BNT162b2 might explain outbreaks in homes for the elderly despite high uptake of the vaccine reported in the press occasionally. Interestingly, VE did not differ between octo- and novo-genarians. The BioNTech-Pfizer efficacy study could not assess VE by outcome due to few hospitalized cases and mortality in the older age groups. Our data

clearly show that VE against hospitalisation after 2 doses is the same as for any SARS-CoV-2 infection and is substantially and significantly higher for COVID-19-related mortality.

Although there was a clear difference in the risk of SARS-CoV-2 infection and COVID-19-related hospitalisation and mortality between men and women, no such difference was observed after vaccination for hospitalisation or mortality, suggesting that BNT162b2 is equally effective for severe outcomes in elderly men and women.

An important study on elderly persons has addressed the onset of effect after one and two doses of the BNT162b2 or the Oxford-AstraZeneca vaccine.¹⁶ The study showed that the VE increases up to 42 days after the first dose and up to after 14 days after the second dose. While the risk for infection decreased only gradually within the first 42 days after the first dose, VE after the second dose already reached 80% after 7 days. During vaccination programmes requiring two doses, it is evident that some persons will only be vaccinated once up to the second dose. In order to estimate the effect of the vaccination programme, it may also be interesting to know the effect of one or more doses. In a population where most second doses were given within 3 weeks after the first dose, VE was found only slightly lower after 2 doses with overlapping 95% CIs.

A strength of our study is the large sample of elderly persons living in Bavaria. Data was retrieved from government data bases and have been checked for implausibilities. Given the structure of the data base for cases which only included date of the last vaccination and number of vaccine doses, we were unfortunately unable to evaluate the VE after the first BNT162b2 vaccine dose. Further, information of risk factors which could contribute to severe COVID-19 disease outcomes in persons aged 80 years and above have not been ascertained for the cases.

In conclusion, we found that two doses of BioNTech-Pfizer's BNT162b2 vaccine provided a high protection against SARS-CoV-2 infection and severe outcomes in elderly persons. There

248 was no difference between octo- and novo-generians and efficacy appeared to be equal in
249 both sexes.

250 **Acknowledgements**

251 We are grateful to the public health offices in Bavaria, Germany who supplied data on cases
252 with SARS-CoV-2 infection and to teams of the Bavarian Corona vaccination portal
253 “BayIMCO” for providing the COVID-19 vaccination data.

254 **Disclosure of conflicts of interest**

255 All authors stated that they had no interests that might be perceived as posing a conflict or
256 bias. As well, they all disclose prior publication and submission of the manuscript.

257 **Author Contributions**

258 **Conceptualization:** Klaus Überla, Rüdiger von Kries

259 **Data Curation:** Delphina Gomes, Andreas Beyerlein, Katharina Katz, Gabriele Hölscher,
260 Uta Nennstiel, Bernhard Liebl

261 **Formal Analysis:** Andreas Beyerlein, Delphina Gomes

262 **Funding Acquisition:** Klaus Überla, Rüdiger von Kries

263 **Investigation:** Rüdiger von Kries

264 **Methodology:** Andreas Beyerlein, Rüdiger von Kries

265 **Project Administration:** Rüdiger von Kries

266 **Software:** Andreas Beyerlein, Delphina Gomes

267 **Supervision:** Rüdiger von Kries

268 **Validation:** Andreas Beyerlein, Delphina Gomes, Rüdiger von Kries

269 **Visualization:** Andreas Beyerlein, Delphina Gomes, Rüdiger von Kries

270 **Writing – Original Draft Preparation:** Delphina Gomes, Andreas Beyerlein, Rüdiger von
271 Kries

272 **Writing – Review & Editing:** Delphina Gomes, Andreas Beyerlein, Katharina Katz,
273 Gabriele Hölscher, Uta Nennstiel, Bernhard Liebl, Klaus Überla, Rüdiger von Kries

References

1. Singhal S, Kumar P, Singh S, Saha S, Dey AB. Clinical features and outcomes of COVID-19 in older adults: a systematic review and meta-analysis. *BMC Geriatr* 2021; **21**(1): 321.
2. Thakur B, Dubey P, Benitez J, et al. A systematic review and meta-analysis of geographic differences in comorbidities and associated severity and mortality among individuals with COVID-19. *Sci Rep* 2021; **11**(1): 8562.
3. Dhama K, Patel SK, Kumar R, et al. Geriatric Population During the COVID-19 Pandemic: Problems, Considerations, Exigencies, and Beyond. *Front Public Health* 2020; **8**: 574198.
4. Bajaj V, Gadi N, Spihlman AP, Wu SC, Choi CH, Moulton VR. Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections? *Front Physiol* 2020; **11**: 571416.
5. Yanez ND, Weiss NS, Romand JA, Treggiari MM. COVID-19 mortality risk for older men and women. *BMC Public Health* 2020; **20**(1): 1742.
6. European Centre for Disease Prevention and Control. Overview of the implementation of COVID-19 vaccination strategies and deployment plans in the EU/EEA – 6 May 2021. ECDC: Stockholm; 2021.
7. Robert Koch-Institut. STIKO-Empfehlungen zur COVID-19-Impfung, 12.05.2021. Germany, 2021.
8. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* 2020; **383**(27): 2603-15.
9. Clinical trial number NCT04368728 for "NCT04368728: Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals" at ClinicalTrials.gov.

10. Fortschreibung des Bevölkerungsstandes (EVAS-Nr. 12411) – Bevölkerung: Bundesländer, Stichtag, Geschlecht, Altersjahre. Statistisches Bundesamt (Destatis). 2020.
11. Bundesministerium für Gesundheit. [Regulation on the extension of the notification obligation according to § 6 para. 1 sentence 1 number 1 and § 7 para. 1 sentence 1 of the German Protection against Infection Act with the novel coronavirus ('2019-nCoV')]. In: German Ministry of Health, 2020.
12. Robert Koch Institute. Case definition: Coronavirus disease-2019 (COVID-19) (SARS-CoV-2) [Faldefinition: Coronavirus-Krankheit-2019 (COVID-19) (SARS-CoV-2)]. In: Berlin 2020.
13. Böhm S, Woudenberg T, Chen D, et al. Epidemiology and transmission characteristics of early COVID-19 cases, 20 January-19 March 2020, in Bavaria, Germany. *Epidemiol Infect* 2021; **149**: e65.
14. Böhmer MM, Buchholz U, Corman VM, et al. Investigation of a COVID-19 outbreak in Germany resulting from a single travel-associated primary case: a case series. *The Lancet Infectious Diseases* 2020; **20**(8): 920-8.
15. Henry D, Jones M, Stehlik P, Glasziou P. Effectiveness of COVID-19 vaccines: findings from real world studies. *MJA*, 2021.
16. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. *BMJ* 2021; **373**: n1088.

Supporting information

S1 Figure. Vaccine efficacy to prevent SARS-CoV-2 infection and related outcomes after at least one BNT162b2 vaccine dose compared to none in Bavarian persons aged 80 years and above.

Vaccine efficacy was calculated as $1 - \text{HR}$ and are adjusted for sex. CI, confidence interval; HR, hazards ratio; VE, vaccine efficacy.